Search Results

Exploring evidence-based approaches to immunology education and their effectiveness in knowledge retention. Immunology underpins many of today’s most significant therapeutic advances, from biologics to personalised medicine. As the field evolves, the effectiveness of immunology education becomes increasingly important. nuaxia conducted a detailed analysis of behavioural data from immunology education activities to assess how learning interventions shape professional competence. By examining pre- and post-education performance, nuaxia’s analysis delivers objective insights into how immunology education influences knowledge retention and clinical understanding, offering a clearer view of educational impact in this rapidly advancing discipline. Key Findings at a Glance 93% of Participants Improved Their Scores Nearly all participants achieved improvements in knowledge and competence, underscoring the tangible benefits of our CME initiatives. 69% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 69% improved 29% remained stable Only 2% saw a decrease This shows that structured medical education adapts to HCPs’ starting points while driving measurable development. 41% Achieved the Top Score After Medical Education Activity Notably, 41% of participants reached the top performance group, showing that CME activities are helping a significant portion of HCPs achieve high performance. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (48.4%) or High (35.6%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the High (45.8%) or Top (41.4%) categories. This shows that well-designed medical education can transform professional performance, not just understanding. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change Not only do HCPs gain from this education, but patients also experience improved outcomes globally. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Funding round will support development of lead targeted alpha therapy ADVC001 in metastatic prostate cancer and expand Lead-212 manufacturing capabilities. AdvanCell has raised $315 million in a Series D financing round backed by major pharmaceutical players including Sanofi and Eli Lilly, as the radiopharmaceutical developer advances its targeted alpha therapy pipeline towards late-stage clinical development. The financing, led by Ally Bridge Group and co-led by Alpha Wave, will support the continued development of AdvanCell’s lead programme, ADVC001, a Lead-212-based radiopharmaceutical currently being evaluated in metastatic prostate cancer. The latest investment builds on growing industry confidence in AdvanCell’s approach to targeted alpha therapies, following Sanofi’s venture arm co-leading the company’s $112 million Series C financing in 2025. The move also follows a strategic collaboration announced between AdvanCell and Lilly, combining AdvanCell’s Lead-212 production capabilities and radionuclide infrastructure with Lilly’s drug development expertise to accelerate the development of targeted alpha therapies. Advancing a New Generation of Radiopharmaceuticals Radiopharmaceuticals have emerged as a major area of oncology investment, using radioactive isotopes attached to targeting molecules to selectively deliver cancer-killing radiation directly to tumour cells. AdvanCell’s technology platform is focused on the scalable and automated production of Lead-212, a promising isotope for targeted alpha therapy applications. The company’s lead candidate, ADVC001, is a Lead-212 PSMA-targeted alpha therapy designed for patients with metastatic prostate cancer. The therapy is currently being evaluated in a Phase II clinical trial, with the latest funding expected to support progression towards Phase III development. AdvanCell is also using the financing to expand its isotope manufacturing infrastructure in the US, addressing one of the key challenges facing the broader radiopharmaceutical sector: reliable, scalable production capacity. Targeting Challenges in Existing Radioligand Therapies Current PSMA-targeted radioligand therapies have demonstrated clinical benefits in prostate cancer, but challenges remain around treatment resistance, tolerability and optimising dosing strategies. AdvanCell believes targeted alpha therapy could help address some of these limitations by delivering highly potent radiation directly to cancer cells while reducing exposure to surrounding healthy tissue. The company’s approach uses Lead-212, which releases alpha particles capable of causing significant tumour cell damage over a short range. This targeted mechanism could potentially improve the therapeutic window compared with broader radiation approaches. Pharma Interest in Radiopharmaceutical Infrastructure The latest financing highlights increasing pharmaceutical interest in radiopharmaceutical platforms, particularly those with the manufacturing capabilities required to support commercial-scale development. “The most enduring healthcare companies combine breakthrough science with the infrastructure and expertise to repeatedly develop new medicines,” said Nik Economopoulos, director of life sciences investments at Alpha Wave. “We believe AdvanCell is building that kind of generational company, with the platform, manufacturing capabilities and pipeline to unlock the full potential of targeted alpha therapies.” Expanding Investor Support Alongside Sanofi and Lilly, the Series D financing included participation from new investors including Bain Capital Life Sciences, Fidelity Management & Research Company, T. Rowe Price Associates, Eventide Asset Management and Velosity Capital. Existing investors including Morningside, SV Health Investors, Abingworth, SymBiosis, Tenmile, Brandon Capital, Piper Heartland, Catalio Capital Management, Proto Axiom and Time BioVentures also participated. With ADVC001 approaching later-stage development and investment accelerating across the radiopharmaceutical landscape, AdvanCell is positioning itself at the intersection of oncology innovation and critical manufacturing infrastructure. The company’s progress reflects a wider industry shift towards precision cancer therapies designed not only around new biological targets, but also around the ability to manufacture and deliver increasingly complex treatments at scale. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Strong private investment signals renewed confidence in the UK life sciences sector, but public markets remain a challenge. The UK biotech sector continued its funding recovery in 2026, with investment reaching a five-year high during the second quarter as venture capital activity surged across the industry. New figures from the UK BioIndustry Association (BIA) show that UK biotech companies secured £2.11 billion ($2.84 billion) in equity financing during Q2 2026, including a record £2.05 billion in venture capital investment. The latest figures build on the positive momentum seen earlier in the year and highlight renewed investor confidence in UK life sciences following a more challenging funding environment in recent years. “This quarter shows continued improvement in funding confidence and deal flow right across the UK biotech sector,” said Chris Molloy, chief executive of the BIA. “Its major headline is the strongest single quarter for UK life sciences venture funding in the last five years.” Isomorphic Labs drives record-breaking quarter The headline figure was heavily influenced by the major fundraising round completed by Isomorphic Labs. The Alphabet-backed company raised £1.6 billion in a Series B financing round in May 2026, representing one of the largest biotech funding events in the UK’s history. However, even excluding Isomorphic Labs’ contribution, the sector still demonstrated meaningful growth. UK biotech companies raised £498 million in venture capital during Q2 2026, compared with £279 million during the same period in 2025. The BIA said the figures demonstrate improving confidence among investors and continued appetite for innovation-led biotech companies. Seed investment remains resilient While large late-stage financings dominated headlines, early-stage investment also remained steady. The BIA reported that seed investment remained resilient during the second quarter, with eight seed financings completed during the period. The organisation highlighted continued institutional support for the sector as a positive indicator for future biotech pipeline development. Early-stage funding remains critical for companies developing novel therapeutics, platforms and technologies, where significant investment is required before clinical validation and commercial opportunities emerge. UK strengthens position as Europe’s leading biotech funding market The UK continued to outperform other European biotech markets during the quarter. UK venture capital investment accounted for 61% of all European biotech venture funding in Q2 2026, compared with 57% during Q1. The BIA said the figures reinforce the UK’s position as Europe’s leading destination for biotech investment. For biotech companies seeking capital to advance clinical programmes, expand research capabilities or scale manufacturing operations, the latest funding data highlights the continued attractiveness of the UK ecosystem. Public markets remain the missing piece Despite strong private investment activity, the BIA warned that public markets have yet to recover at the same pace. No UK biotech companies completed an initial public offering (IPO) during 2026, highlighting the ongoing gap between private financing strength and public market support. “UK public markets need to recognise, cover and return to backing our sector and private momentum must be joined by robust, public sector-managed, investor-advised translational funding,” Molloy said. The lack of IPO activity remains a challenge for biotech companies looking to transition from venture-backed growth businesses into publicly traded organisations. What does this mean for UK biotech? The latest funding figures provide a positive signal for the UK life sciences sector, showing that investor appetite is returning for innovative biotech companies. Strong venture capital flows could help accelerate the development of new medicines, support emerging platforms such as artificial intelligence-driven drug discovery, and strengthen the UK’s role in global pharmaceutical innovation. However, maintaining this momentum will require progress beyond private investment, with improved public market confidence needed to support companies through later stages of growth. For UK biotech, 2026 is shaping up as a year of renewed optimism — but converting funding momentum into long-term industry growth will depend on continued support across the entire innovation ecosystem. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The once-daily tablet provides a new oral option for reducing LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia. The FDA has approved Lipfendra (enlicitide) as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia. As the first oral therapy to inhibit PCSK9, Lipfendra expands treatment choice beyond the injectable PCSK9 therapies previously available. Field Content Alert Type Drug Approval Drug Name Lipfendra Indication Reduction of LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia Therapy Area(s) Cardiology Geography US (FDA) What Changed The FDA approved Lipfendra (enlicitide) on 16 July 2026 as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia. It is the first orally administered drug approved to inhibit PCSK9. Clinical Relevance Provides a once-daily oral PCSK9 treatment option for adults requiring LDL-cholesterol reduction, expanding choice beyond injectable PCSK9 therapies. Source Link FDA approval notice. Date 16 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The spin-out creates a dedicated US oncology company to raise capital and advance Lupin’s PRMT5 and SOS1 programmes through global clinical development. Lupin has granted Kaveri Therapeutics exclusive, perpetual licences to two clinical-stage oncology programmes—LNP7457 and LNP8701—in exchange for an 82.2% equity stake, with the assets valued at $1.6 million. The arrangement is intended to accelerate their development through an independently managed oncology company that will seek external funding for global clinical trials. Field Content Alert Type Deal Companies Lupin Inc., the wholly owned US subsidiary of Lupin Limited, and Kaveri Therapeutics Deal Type Strategic spin-out and exclusive perpetual licensing agreement involving an 82.2% equity stake Asset or Company LNP7457, a PRMT5-targeting programme, and LNP8701, a SOS1-targeting programme Therapy Area(s) Oncology Technology or Modality Targeted small-molecule oncology therapies Deal Value The two licensed programmes were valued at $1.6 million. Lupin received 332,000 common shares representing an 82.2% stake in Kaveri and will also provide seed funding, the amount of which was not disclosed. Development Stage Clinical-stage programmes in early clinical development Geography US-based transaction with planned global clinical development What Happened Lupin granted Kaveri exclusive, perpetual licences to LNP7457 and LNP8701 in exchange for an 82.2% equity stake. The transaction was completed on 20 July 2026, and Kaveri will assume responsibility for advancing the programmes through global clinical trials. Background Kaveri was incorporated in Delaware in May 2026 as a clinical-stage oncology company focused on solid tumours, including lung, pancreatic, ovarian and CNS-related cancers. Lupin reported that LNP7457 and LNP8701 presented positive clinical data at the 2025 and 2026 ASCO meetings, respectively. Strategic Rationale The structure places the two programmes within a dedicated, independently managed oncology company that can raise external capital and focus on global clinical development, while Lupin retains a majority equity interest in their future progress. Why It Matters The deal gives the programmes a specialised development vehicle and access to additional financing without Lupin relinquishing its majority economic interest. It also expands Kaveri’s pipeline across two targeted mechanisms relevant to difficult-to-treat solid tumours. Potential Impact Successful fundraising could support broader global trials and biomarker-driven development of the PRMT5 and SOS1 programmes, although their eventual clinical and commercial value will depend on future trial results. Key Takeaway Lupin is using a majority-owned spin-out to pursue external funding and focused clinical development for two targeted oncology assets. What to Watch Kaveri’s planned capital raise, the design and progression of global clinical trials, future data from both programmes and any additional financing or partnership arrangements. Source Link Lupin regulatory filing and accompanying company press release Deal Date 21 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The designation supports development of a one-time investigational gene therapy designed to address the underlying genetic cause of a rare form of dilated cardiomyopathy. The FDA has granted orphan drug designation to Affinia Therapeutics’ AFTX-201 for the treatment of BAG3-associated dilated cardiomyopathy. The designation provides development incentives for the investigational AAV gene therapy, which is being studied in the Phase 1/2 UPBEAT trial and has not received marketing approval. Field Content Alert Type Regulatory Designation – Orphan Drug Drug Name AFTX-201 Indication Treatment of BAG3-associated dilated cardiomyopathy Therapy Area(s) Cardiology; Rare disease Geography US (FDA) What Happened Affinia Therapeutics announced on 22 July 2026 that the FDA had granted orphan drug designation to AFTX-201 for BAG3-associated dilated cardiomyopathy. AFTX-201 is an investigational AAV gene therapy designed to deliver a functional BAG3 transgene through a single intravenous infusion; the designation is not a marketing approval. Why It Matters Orphan drug designation provides incentives intended to support development of treatments for rare diseases, including potential tax credits, exemption from certain FDA application fees and seven years of market exclusivity if the product is later approved. It does not establish that AFTX-201 is safe or effective. Supporting Context BAG3-associated dilated cardiomyopathy is caused by genetic changes that reduce BAG3 protein in heart cells and can lead to early-onset progressive heart failure. No approved treatment currently addresses the underlying genetic mechanism, while AFTX-201 is being evaluated in the recruiting Phase 1/2 UPBEAT trial. Key Takeaway The designation provides regulatory and development support for AFTX-201 but does not constitute FDA approval of the therapy. What to Watch Safety, tolerability and preliminary efficacy findings from the UPBEAT trial, together with any subsequent FDA development or review milestones. Primary Source Affinia Therapeutics’ official announcement Relevant Date 22 July 2026 — company announcement date Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Examining the latest strategies, trends, and outcomes in respiratory education to drive measurable improvements. In respiratory medicine, where disease burden continues to rise globally, the role of effective medical education has never been more critical. But how well does respiratory-focused education translate into meaningful learning outcomes? At nuaxia, we analysed behavioural data from respiratory education activities to understand how learning interventions influence knowledge and competence among healthcare professionals. Using advanced analytical techniques, nuaxia assessed changes in learner performance before and after respiratory education initiatives. By examining patterns in engagement, knowledge acquisition and competence development, this analysis offers clear, objective insights into what works and where respiratory education delivers the greatest impact. Key Findings at a Glance 93% of Participants Improved Their Scores The vast majority of participants attained significant gains in knowledge and competence, highlighting the strong learning value embedded in our CME activities. 67% of Participants Moved Up One or More Score Groups Through data clustering into four distinct groups (Low, Average, High, and Top), we tracked significant upward movement: 67% improved 31% remained stable Only 2% saw a decrease This demonstrates how targeted education engages HCPs at their current level and supports meaningful professional growth. 46% Achieved the Top Score After Medical Education Activity Perhaps most impressively, nearly half of all participants reached the top performance group, indicating that CME activities are not only raising the bar but also helping HCPs reach it. Score Distribution: Before vs. After Baseline Scores: Most participants began in the High (50.1%) or Average (38.6%) categories. Post-Activity Scores: The distribution shifted significantly, with most participants now in the Top (45.6%) or High (41.2%) categories. This demonstrates that high-quality medical education not only teaches but also empowers HCPs to apply what they learn. Why These Results Matter In an era where evidence-based practice is critical, these results provide compelling proof that targeted, high-quality medical education can: Close knowledge gaps Elevate clinical competence Drive behavioural change These improvements benefit HCPs and contribute to better patient outcomes worldwide. Our Methodology The analysis was based on: 180 educational activities 8 individual therapeutic areas Participants with at least 3 data points at both baseline and post-activity Clustering was done using silhouette scoring, which optimises groupings for analytical clarity. This ensures that the insights gained are both scientifically valid and actionable. Looking Ahead These insights reinforce the value of data-driven decision-making in medical education. If you're planning a new CME programme or want to measure the impact of your current educational initiatives, nuaxia’s database and analytics capabilities can help you deliver outcomes that matter. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Kardigan has made a strong public market entrance, with shares jumping more than 37% on its first day of trading following a $400 million initial public offering that underscores continued investor appetite for biotech listings. The cardiovascular-focused company upsized its IPO ahead of pricing, ultimately selling 25 million shares at $16 each, the top end of its revised range. The offering had initially targeted 23.3 million shares priced between $14 and $16. The debut places Kardigan among the largest biotech IPOs of 2026 so far, tied for third alongside Generate:Biomedicines. It follows closely behind Parabilis Medicines, which raised $670 million, and Kailera Therapeutics, which raised $625 million in earlier listings this year. Strong First-Day Performance Signals Continued Biotech Risk Appetite The sharp first-day gain reflects sustained investor demand for differentiated biotech assets despite a volatile funding environment. Public market enthusiasm has been particularly concentrated in companies with clearly defined therapeutic areas and late-stage or de-risked clinical programmes, with cardiovascular disease emerging as a notable area of interest alongside oncology and obesity. Kardigan’s listing adds further momentum to what has already been a record-setting year for biotech IPO activity. Pipeline Built Around Cardiovascular Disease Mechanisms Proceeds from the IPO will be used to advance Kardigan’s pipeline of therapies targeting the underlying mechanisms of cardiovascular disease. The company’s lead asset, danicamtiv, was in-licensed from Bristol Myers Squibb and is currently being evaluated in the Phase IIb/III KINSHIP-DCM study in patients with genetic dilated cardiomyopathy associated with MYH7 and TTN mutations. Danicamtiv sits at the centre of Kardigan’s strategy to address inherited and mechanistic drivers of cardiac dysfunction rather than symptom management alone. The company is also developing ataciguat, an oral soluble guanylate cyclase activator, currently in a Phase IIb study for calcific aortic valve stenosis under the KATALYST-AV trial. A third programme, tonlamarsen, is a liver-directed antisense oligonucleotide in Phase II development for severe hypertension following hospitalisation in the KARDINAL-ASH study. Each asset targets distinct but interconnected cardiovascular pathways, reflecting a broader industry shift toward mechanism-based approaches in cardiometabolic disease. IPO Market Continues to Favour Defined Clinical Narratives Kardigan’s successful debut adds to a growing pattern in biotech public offerings, where investor attention has increasingly gravitated toward companies with clear mechanistic hypotheses and focused disease areas. Cardiovascular disease, long considered a challenging but high-value therapeutic area, is seeing renewed interest as genetic insights and precision medicine approaches reshape development strategies. The strong IPO performance suggests that, despite broader market uncertainty, capital remains available for companies with credible clinical differentiation and defined late-stage assets. A Strong Start, but Clinical Execution Now in Focus While the IPO marks a successful entry into public markets, Kardigan now faces the next phase of scrutiny as it advances its clinical programmes toward key data readouts. The company’s ability to translate its mechanistic pipeline into clinical and regulatory success will ultimately determine whether early investor enthusiasm is sustained beyond the initial trading momentum. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The two-year tariff-free window could prompt overseas manufacturers and US importers to reassess production, investment and sourcing before higher duties take effect. President Donald Trump has announced that generic drugs imported into the US will remain subject to a zero tariff for two years from 1 August 2026, followed by a 100% tariff for one year and a 200% tariff thereafter. If formalised, the timetable could materially change the economics of supplying the US generics market and increase pressure on manufacturers to establish domestic production. Field Content Alert Type Industry Update Topic Trade policy and pharmaceutical manufacturing Organisation(s) US administration; President Donald Trump Affected Stakeholders Overseas generic-drug manufacturers, US pharmaceutical importers and companies reliant on imported generic products or ingredients Geography US What Happened Trump announced that imported generic drugs would retain a zero tariff for two years from 1 August 2026. The announced rate would then rise to 100% for one year and 200% thereafter, with the stated aim of encouraging generic-drug manufacturers to build production capacity in the US. The announcement did not itself provide the formal tariff classifications, exemptions or implementation mechanism. Why It Matters The proposed rates could substantially alter manufacturing and sourcing decisions for companies supplying generic medicines to the US. The two-year transition gives affected businesses time to evaluate domestic investment, but the commercial consequences will depend on the final scope and rules. Supporting Context An April 2026 presidential proclamation imposed tariffs on certain patented pharmaceutical products but stated that generic pharmaceuticals, associated ingredients and biosimilars would not be subject to Section 232 tariffs at that time. It also required the Department of Commerce to report within one year on circumstances that might support further action on generic imports. Who Is Most Affected Foreign manufacturers supplying generic medicines to the US face the clearest potential exposure. US importers may need to review suppliers and costs, while domestic manufacturers could gain a stronger incentive to expand capacity. Industry Impact If implemented as announced, the policy could accelerate US manufacturing investment and encourage supply-chain restructuring. Its effect on medicine costs, competition and availability would depend on whether manufacturers can establish sufficient domestic capacity and on any exemptions included in the formal rules. Key Takeaway Generic-drug manufacturers have been given an announced two-year planning window, but formal implementation details will determine which products and companies are ultimately affected. What to Watch A presidential proclamation, Federal Register notice or Department of Commerce guidance confirming the legal basis, covered tariff codes, treatment of active pharmaceutical ingredients and biosimilars, exemptions and criteria for qualifying US investment. Primary Source President Donald Trump’s Truth Social announcement Relevant Date 21 July 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com